Drug intelligence / Profile preview

Tiaoshen Xuanluo Changmu formula

Development stage: Preclinical
Lead developer: Yunnan Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Tiaoshen Xuanluo Changmu formula is a Traditional Chinese Medicine (TCM) formula under investigation for the treatment of intrauterine adhesion after transcervical resection of adhesion (TCRA). It is specifically aimed at patients diagnosed with kidney deficiency and blood stasis type, with the therapeutic goal of improving endometrial blood flow.

Beyond the preview

Go deeper on Tiaoshen Xuanluo Changmu formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaoshen Xuanluo Changmu formula.

Explore the full profile